The research group at Lund University, that runs DiAPREV-IT, a clinical study evaluating if the diabetes vaccine Diamyd® can prevent or delay the onset of type 1 diabetes in children at high risk of developing the disease, has applied to the Swedish Medical Products Agency to expand the study with an additional 50 children. The first part of the study, which also comprises 50 children, is fully recruited and results are expected in 2015. “To expand this unique study is important as the chance to demonstrate a statistically significant effect of Diamyd’s diabetes vaccine increases the more children that are enrolled in the study,“ says Peter Zerhouni, President and CEO of Diamyd Medical. “Type 1 diabetes is a lifelong and serious disease and if it could be prevented or delayed it would avoid a lot of worrying, suffering and costs for the children and their families as well as for the society. There is no treatment available today that can prevent or delay the disease process.” DiAPREV-IT, which was started in 2009, is a double-blind and placebo-controlled clinical study which to date has enrolled 50 children from four years of age. Half of the children have been treated with the diabetes vaccine Diamyd® and half with placebo (a non-active substance). The children are currently in follow -up and the first results of the study are expected in 2015. The Sponsor and Principal Investigator of the study, Helena Elding Larsson, pediatrician in Malmoe and researcher at Lund University in Sweden, has now applied to the Swedish Medical Products Agency to enroll an additional 50 children at high risk of developing type 1 diabetes. In the expanded part of the study two thirds of the children are planned to receive active diabetes vaccine and one third placebo. When the 50 new children have been in the study for three years the results of all 100 children are planned to be pooled and analyzed. ”The scientific value of the study will be much enhanced if we can double the number of participants,” says Doctor Helena Elding Larsson. “Also, it is fantastic to be able to offer something to these children that we know, by analyzing their genetic risk and biomarkers in their blood, are at high risk of developing type 1 diabetes. Half of them are expected to present with the disease within only five years. Just delaying the disease with the help of the diabetes vaccine would represent a medical breakthrough.” In addition to the DiAPREV-IT study described above, the enrollment of patients to another researcher initiated Phase II study with the diabetes vaccine Diamyd® is underway at around ten pediatric diabetes clinics across Sweden. In that study, called DIABGAD-1, children and adolescents recently diagnosed with type 1 diabetes are treated with the diabetes vaccine Diamyd® in combination with vitamin D and ibuprofen. That study aims to investigate whether the treatment can preserve the body’s capacity to make insulin. Some insulin producing capacity reduces the risk of both acute and long-term diabetes complications. The first results from DIABGAD-1 are expected to be presented in 2015. About Type 1 Diabetes Type 1 diabetes is an autoimmune form of diabetes that ordinarily occurs in children. The disease is caused by an autoimmune attack, which means that the body’s own immune system destroys the insulin-producing beta cells in the pancreas that control the blood sugar. To survive with type 1 diabetes intensive treatment with insulin is needed every day for life, either through injections or an insulin pump, and the blood sugar must be checked through blood samples 7 -10 times a day. Both too much and too little insulin can lead to unconsciousness and even death. Type 1 diabetes can also cause serious long-term complications, such as blindness, cardiovascular disease, nephropathy and neuropathy. Today there is no cure for type 1 diabetes and the disease cannot be prevented. It is estimated that approximately 80,000 persons per year are diagnosed with type 1 diabetes in the US and Europe alone. The Nordic countries have the highest incidence of type 1 diabetes in the world. In Sweden two children are diagnosed with type 1 diabetes every day. For further information, please contact: Peter Zerhouni, President and CEO Diamyd Medical AB Phone: +46 8 661 00 26. E-mail: press@diamyd.com About Diamyd Medical Diamyd Medical is a Swedish diabetes company. The Company’s primary development project consists of the GAD-based diabetes vaccine Diamyd®for the treatment and prevention of autoimmune diabetes. Two Swedish researcher-initiated Phase II studies with Diamyd®are ongoing. One study evaluates whether the diabetes vaccine can prevent type 1 diabetes in children who are at high risk of developing the disease, while the other study evaluates whether Diamyd®in combination with vitamin D and ibuprofen can preserve the body's own ability to regulate the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes. In May 2013 the Company concluded an exclusive licensing agreement with the University of California in Los Angeles (UCLA) relating to a patent portfolio for the therapeutic use of GABA (gamma-aminobutyric acid) and GABA receptor agonists for the treatment and prevention of type 1 and type 2 diabetes and other inflammation-related conditions, such as metabolic syndrome, rheumatoid arthritis and allergies. Diamyd Medical also has holdings in the gene therapy company Periphagen Holdings, Inc. (US). Diamyd Medical’s Series B share is traded on NASDAQ OMX First North under the ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser. Further information is available on the Company’s website: www.diamyd.com. Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com. Reg. no.: 556242-3797.
Application to double unique study with Diamyd’s diabetes
Top 10 Most Recent News Articles
ASTS Faces Class Action: Investor Warning Ahead
AST SpaceMobile: Turbulence Ahead? The latest buzz isn't coming from AST SpaceMobile's satellites but from courtrooms, with a class action lawsuit raising eyebrows among NASDAQ:ASTS investors. It's like watching a high-stakes poker game where cards have hidden costs, and the patience of those holding them is wearing thin. Here's what's truly ruffling feathers. What...
Continue Reading
MSM's New Tool Tackles Label Errors with AI Insight
Nailing Label Precision in Real Time The label printing game just got a major new player. MSM Solutions is rolling out its PortalTrack Print Quality Inspection, and it's not just another tool in the shed—this thing's promising to cut down on label errors before they can bite. Imagine turning your good old industrial label printers into sharp-eyed inspectors, thanks to...
Continue Reading
RPC Reports Q3 Loss Amid Revenue Growth Quirks
RPC Rides Out a Rough Quarter with Strategic Moves Ah, the oilfield services game—never a dull moment, right? RPC, Inc. just dropped their Q3 2026 results, and there’s a mixed bag to digest here. On the one hand, they saw a modest 1% uptick in revenue, hitting $467.7 million. But on the flip side, they're grappling with a hefty net loss of $41.9 million thanks to a...
Continue Reading
Scientology Aids in Huge Meal Effort After Hurricane
Weathering the Storm and Feeding the Survivors Alright, so here's the thing—when a hurricane hits, it doesn't just mess up your weekend plans. We're talking about massive upheaval, like making more than 900,000 folks powerless in the Florida Panhandle. No electricity means no cooking, and in comes the disaster crew to save the day. Enter the Churches of Scientology...
Continue Reading
A2Gold Divests Bolo in Strategic $1.5 Million Sale
A2Gold Shifts Focus, Cashes in on Bolo You catch wind of A2Gold's latest move, and it's not just some footnote. This outfit's unloading its interest in the Bolo Gold Project over in Nye County, Nevada, to Super Gold Mining Corp. You'd think they're just getting rid of excess baggage, but there's more under the hood. Breakdown of the Deal The transaction's worth C$1.5...
Continue Reading
Innovative Sonar System Seeks to Simplify Fishing Boats
Navigating the Clutter on Fishing Boats You ever try setting up a sonar system on a fishing boat? It's like untangling a mess of Christmas lights. The cables, the hubs, the separate units—it’s chaos. Here's where a crafty inventor from Zumbro Falls, Minnesota, steps into the ring with an idea that's as refreshing as an ice-cold beer on a summer’s day: a centralized...
Continue Reading
HR HealthCare Foundation: New Chapter of Giving
HR HealthCare Reaffirms Commitment Through New Foundation The corporate world didn't see this one coming. On October 29, 2026, HR HealthCare, a stalwart in the healthcare products arena, has decided to double down on its benevolent side by establishing the HR HealthCare Foundation. It ain't just about selling widgets anymore; it's about making a genuine impact outside the...
Continue Reading
Why Haunted Attractions Keep Us Coming Back for Fear
Welcome to Fear Incarnated Ah, Kansas City. More than just jazz and barbeque. You’ve got these infamous haunted houses that turn every horror flick into a mere Saturday morning cartoon. Enter Edge of Hell and Beast Haunted Attraction. Two horrifying museums of fear that somehow lure us like flies to sugar from miles away. What's the secret sauce? Well, that’s half the...
Continue Reading
Cerebras Faces Durability Allegations: Investor Alert
Cracks in Cerebras' Processor Promises? When you dance with high-stakes tech stocks, sometimes you end up stepping on a few toes. This seems to ring true as Cerebras Systems (CBRS) dances its way into hot water. Allegations from Culper Research suggest their fancy AI processors, which are supposed to be the poster children of reliability, might bow out early. Digging...
Continue Reading
Bulletproof Gets Nod for AI Expertise, Eyes Future Growth
Bulletproof's Recognition: A Sign of AI Prowess Let's dive right into today's news: Bulletproof just snagged a spot on the 2026 CRN AI Innovators list. Now, this is big leagues stuff, especially since this list highlights the top dogs in the AI space across North America. We're talking about managed service providers, value-added resellers, and all those tech wizards who...
Continue ReadingTop 5 Most Recently Viewed Articles
Expert Advice on Neighborhood Selection from Ryan Lerwill
Finding the Perfect Neighborhood: Insights from Ryan Lerwill Homebuyers often face the challenge of choosing a neighborhood that suits their preferences and lifestyle. Ryan Lerwill, a renowned real estate expert, offers invaluable advice on making this important decision. In his recent discussion, he emphasizes the significance of various factors that influence how...
Continue Reading
Strategic Insights on Market Trends and Economic Indicators
Understanding Recent Market Dynamics Today offers an opportunity to gain valuable insights into market movements driven by economic data and trends. As we delve into the intricate world of investing, understanding these fluctuations is essential. Critical Economic Data on the Horizon Investors should focus on two significant economic indicators scheduled for release soon....
Continue Reading
Exciting New Lunch Meats from Hillshire Farm® Available Now
Introducing Bold New Flavors from Hillshire Farm® Tyson Foods is excited to invigorate the lunch meat category with the launch of the new Hillshire Farm Sandwich Style Lunch Meats. These innovative products are designed to not only satisfy hunger but also to elevate the everyday meal experience with exciting flavors. Explore the New Flavors Hillshire Farm has unveiled...
Continue Reading
Technetium-99m Market Growth Projections for Medical Imaging
Technetium-99m Market Overview The Technetium-99m market is undergoing remarkable growth due to its critical use in medical diagnostics. Particularly known for its application in imaging chronic and non-communicable diseases, the market value stands at approximately US$ 6.0 billion. Projections indicate that this value could grow by a compound annual growth rate (CAGR) of...
Continue Reading
Jazz Chisholm Jr. Expands His Brand with Once Upon a Coconut
Jazz Chisholm Jr. Joins Once Upon a Coconut Once Upon a Coconut is making waves in the coconut water industry, and now they have an exciting new partner: Jazz Chisholm Jr., the talented second baseman for the New York Yankees. This partnership highlights Chisholm's dynamic nature, not just as an athlete but as a passionate advocate for positive change. Known for his...
Continue Reading